The estimated Net Worth of Stephen L. Eck is at least $638 Mille dollars as of 15 February 2024. Dr Eck owns over 16,670 units of Macrogenics Inc stock worth over $60,345 and over the last 9 years he sold MGNX stock worth over $0. In addition, he makes $577,625 as Sr. VP of Clinical Devel. & Chief Medical Officer at Macrogenics Inc.
Sign up
Dr Eck MGNX stock SEC Form 4 insiders trading
Dr has made over 2 trades of the Macrogenics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 16,670 units of MGNX stock worth $60,345 on 15 February 2024.
The largest trade he's ever made was exercising 16,670 units of Macrogenics Inc stock on 15 February 2024 worth over $60,345. On average, Dr trades about 1,511 units every 84 days since 2016. As of 15 February 2024 he still owns at least 16,670 units of Macrogenics Inc stock.
You can see the complete history of Dr Eck stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Stephen L. Eck biography
Dr. Stephen L. Eck is the Sr. VP of Clinical Devel. & Chief Medical Officer at Macrogenics Inc.
What is the salary of Dr Eck?
As the Sr. VP of Clinical Devel. & Chief Medical Officer of Macrogenics Inc, the total compensation of Dr Eck at Macrogenics Inc is $577,625. There are 5 executives at Macrogenics Inc getting paid more, with Dr. Scott Koenig M.D., Ph.D. having the highest compensation of $1,045,415.
How old is Dr Eck?
Dr Eck is 66, he's been the Sr. VP of Clinical Devel. & Chief Medical Officer of Macrogenics Inc since . There are 3 older and 5 younger executives at Macrogenics Inc. The oldest executive at Macrogenics Inc is Dr. Scott Koenig M.D., Ph.D., 69, who is the CEO, Pres & Director.
Insiders trading at Macrogenics Inc
Over the last 11 years, insiders at Macrogenics Inc have traded over $27,036,278 worth of Macrogenics Inc stock and bought 4,026,274 units worth $39,875,062 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Target N Vbb Biotech Ag Bio... e Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $132,068. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth $16,290.
What does Macrogenics Inc do?
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
What does Macrogenics Inc's logo look like?
Complete history of Dr Eck stock trades at Luminex Corp e Macrogenics Inc
Macrogenics Inc executives and stock owners
Macrogenics Inc executives and other stock owners filed with the SEC include:
-
Dr. Scott Koenig M.D., Ph.D.,
CEO, Pres & Director -
Dr. Scott Koenig,
CEO, Pres & Director -
Dr. Ezio Bonvini,
Sr. VP of Research & Chief Scientific Officer -
James Karrels,
Sr. VP, CFO & Corp. Sec. -
Eric Blasius Risser,
Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer -
Dr. Stephen L. Eck,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Stephen L. Eck M.D., Ph.D.,
Sr. VP of Clinical Devel. & Chief Medical Officer -
Dr. Christopher Shayne James M.D.,
VP of Investor Relations & Corp. Communications -
Lynn Cilinski,
VP, Controller & Treasurer -
Dr. Thomas M. Spitznagel,
Sr. VP of BioPharmaceutical Devel. & Manufacturing -
Jeffrey Stuart Peters,
Sr. VP & Gen. Counsel -
Anna Krassowska Ph.D.,
VP of Investor Relations & Corp. Communications -
David C Stump,
Director -
Kenneth Galbraith,
Director -
Lynn Cilinski,
VP, Controller and Treasurer -
Atul Saran,
See remarks -
Scott Thomas Jackson,
Director -
Karen Jean Ferrante,
Director -
Edward Hurwitz,
Director -
Matthew K Fust,
Director -
Ezio Bonvini,
Sr VP, Research & CSO -
Paulo F Costa,
Director -
Scott Koenig,
President and CEO -
Jay Philip Siegel,
Director -
Jon Marc Wigginton,
Sr VP, Clinical Dev. & CMO -
Kathryn E Stein,
Senior VP, Prd Dev & Reg Aff -
Stanford John Stewart,
V P, Clinical Oncology -
Biopharma Partners Iii Lpal...,
-
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Arnold L Oronsky,
Director -
James Karrels,
SVP, CFO and Secretary -
William K Heiden,
Director -
Stephen L. Eck,
Chief Medical Officer -
Federica F. O'brien,
Director -
Eric Blasius Risser,
Chief Operating Officer -
Jeffrey Stuart Peters,
Senior VP and General Counsel -
Thomas Spitznagel,
Sr VP, Technical Ops -
Target N Vbb Biotech Ag Bio...,
-
Margaret Liu,
Director -
Meenu Chhabra,
Director